Aims Schizophrenia has the highest median societal cost per patient of all mental disorders.
This review summarizes the different costs/cost drivers (cost components) associated with …

Highlights•Drugs for schizophrenia are often based on dopamine blockade and have
serious side-effects.•Xanomeline/trospium may well herald the first non-dopamine based …

Background Based on the neuroinflammation hypothesis in schizophrenia and known anti-
inflammatory effects of berberine, the aim of the present study is to investigate the efficacy of …

Negative symptoms are core symptoms of schizophrenia which are common throughout the
course of the illness. We outline their functional impact, before reviewing the latest research …

Schizophrenia is among the fifteen most disabling diseases worldwide. Negative symptoms
(NS) are highly prevalent in schizophrenia, negatively affect the functional outcome of the …

Executive Summary The Mental and Substance Use Disorders Prevalence Study (MDPS) is
a pilot program designed to determine the lifetime prevalence rates and past-year …

Background Low-and middle-income countries (LMICs) have the highest socio-economic
burden of mental health disorders, yet the fewest resources for treatment. Recently, many …

Background Schizophrenia is a chronic persistent disease with high recurrence rate and
high disability rate in the field of psychiatry. Sodium nitroprusside is a nitric oxide (NO) donor …

The profound economic burden of schizophrenia is due, in part, to the negative symptoms of
the disease, which can severely limit daily functioning. There is much debate in the field …

Background Schizophrenia is a common mental disorder that seriously affects patients' daily
lives and brings heavy psychological and economic burdens to their families and society …